Black Hawk Acquisition

BKHANasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$49.801 M

$11.99 +0.00%

Close of 21 Sept 2026

Revenue

—

Not reported

Earnings

$1.33M

#2341 by earnings

Shares outstanding

4,153,577

Latest filing cover page

P/E ratio

37.5

Cap ÷ net income

Other share classes

Black Hawk Acquisition lists more than one class of stock. Company figures above cover all classes combined.

BKHAR BKHAU

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 160 →

#126Greenland MinesGRML$55.1M
#127ImageneBioIMA$54.6M
#128Black Hawk AcquisitionBKHA$49.8M
#129TevogenTVGN$48.4M
#130Instil BioTIL$47.9M

What if Black Hawk Acquisition were worth as much as…

Open the what-if tool →

Gold $30.3T

$7,288,670

Per share 607,896× higher

Bitcoin $1.72T

$414,053.65

Per share 34,533× higher

Nvidia $5.48T

$1,319,311

Per share 110,034× higher

Or at a round number

$100.0M $200.0M $500.0M $1.00B

Where these numbers come from

Share counts and financials for Black Hawk Acquisition are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 22 Sept 2026. Read the methodology.